Correlation of clinical outcomes with β-glucan levels in patients with invasive candidiasis

Journal of Clinical Microbiology

Volumn 50, Issue 6, 2012, Pages 2104-2106

  Sims, Charles R ^a   Jaijakul, Siraya ^a   Mohr, John ^b   Rodriguez, Jose ^a   Finkelman, Malcolm ^c   Ostrosky Zeichner, Luis ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b CUBIST PHARMACEUTICALS INC   (United States)

^c Associates of Cape Cod   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; BETA GLUCAN; ECHINOCANDIN; FLUCONAZOLE; POLYENE;

ADOLESCENT; ADULT; AGED; ARTICLE; BETA GLUCAN BLOOD LEVEL; BLOOD CULTURE; BLOOD LEVEL; BLOOD SAMPLING; CANDIDIASIS; CLINICAL ASSESSMENT; DISEASE MARKER; DRUG TREATMENT FAILURE; HUMAN; MAJOR CLINICAL STUDY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; SEROLOGY; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; BETA-GLUCANS; CANDIDIASIS, INVASIVE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SERUM; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84862059147     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.00773-12     Document Type: Article

References (9)

1. De Pauw B, et al. 2008. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin. Infect. Dis. 46:1813-1821.
2. Kaji Y, Hiraoka T, Oshika T. 2004. Potential use of (1,3)-beta-D-glucan as target of diagnosis and treatment of keratomycosis. Cornea 23(Suppl 8):S36-S41. (Pubitemid 39458542)
3. Karageorgopoulos DE, et al. 2011. β-D-Glucan assay for the diagnosis of invasive fungal infections: a meta-analysis. Clin. Infect. Dis. 52:750-770.
4. Kondori N, Edebo L, Mattsby-Baltzer I. 2004. Circulating beta (1-3) glucan and immunoglobulin G subclass antibodies to Candida albicans cell wall antigens in patients with systemic candidiasis. Clin. Diagn. Lab. Immunol. 11:344-350. (Pubitemid 38380816)
5. Nett J, Lincoln L, Marchillo K, Andes D. 2007. Beta-1,3 glucan as a test for central venous catheter biofilm infection. J. Infect. Dis. 195:1705-1712. (Pubitemid 46799229)
6. Odabasi Z, et al. 2004. Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin. Infect. Dis. 39:199-205. (Pubitemid 38971490)
7. Pappas PG, et al. 2009. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 48:503-535.
8. Rex JH, Walsh TJ, Anaissie EJ. 1998. Fungal infections in iatrogenically compromised hosts. Adv. Intern. Med. 43:321-371.
9. Wenzel RP. 1995. Nosocomial candidemia: risk factors and attributable mortality. Clin. Infect. Dis. 20:1531-1534.